Johnson & Johnson (NY:JNJ)

Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson (NYSE: JNJ) revealed 17 unusual trades.

Topics Intellectual Property

Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity ↗

September 25, 2025

Via Benzinga

What's Driving the Market Sentiment Around Johnson & Johnson? ↗

September 25, 2025

Johnson & Johnson's (NYSE: JNJ) short interest as a percent of float has risen 17.95% since its last report. According to exchange reported data, there are now 22.05 million shares sold short, which is...

Via Benzinga

US Stocks Grapple with Quarter-End Jitters, Two-Day Losing Streak Tests Market Resolve

September 25, 2025

New York, NY – September 25, 2025 – As the third quarter of 2025 rapidly approaches its conclusion, U.S. stock markets are navigating a challenging period, marked by a two-day losing streak that...

Market Tremors: Dow, S&P 500, and Nasdaq Endure Third Straight Day of Losses Amidst Economic Headwinds

Topics Artificial Intelligence Economy Stocks

September 25, 2025

New York, NY – September 25, 2025 – Major U.S. stock indices, including the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite, have registered their third consecutive day of declines,...

Johnson & Johnson (JNJ) shows a strong technical uptrend and a high-quality consolidation pattern, signaling a potential breakout as it trades near 52-week highs.

Topics Artificial Intelligence Economy Stocks

Johnson & Johnson (NYSE:JNJ) Shows Strong Technical Setup for Potential Breakout ↗

September 25, 2025

Via Chartmill

These 3 Dow Stocks Are Set to Soar in 2025 and Beyond ↗

September 25, 2025

The proverbial planets are aligning for each of their underlying companies.

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish ↗

Topics Artificial Intelligence Stocks

September 22, 2025

3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years ↗

Topics Government

September 25, 2025

Not only have these stocks raised their dividends consistently, but they also offer above-average yields.

Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence...

Topics Economy

Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects

September 24, 2025

A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program.

Topics Government Product Recall

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies ↗

September 24, 2025

Via Benzinga

Johnson & Johnson Is Attacking 2022 Highs ↗

September 24, 2025

Johnson & Johnson is attacking 2022 highs, as we see it rising impulsively, ideally unfolding a five-wave bullish cycle of different degrees by the Elliott wave model.

Via Talk Markets

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’ ↗

September 23, 2025

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Topics Economy Government Lawsuit

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

Via Benzinga

Jabil Set For Major AI Growth As Other Segments Falter: Analyst ↗

September 23, 2025

Jabil Inc. to report fiscal Q4 earnings; AI and cloud revenue key factors for outlook. Analyst expects conservative guidance.

Via Benzinga

Topics Artificial Intelligence

Evolving Investment Strategies for an Uncertain Market

September 23, 2025

In an era marked by persistent inflation, fluctuating interest rates, geopolitical tensions, and rapid technological shifts, investors are facing an increasingly complex and unpredictable financial...

Johnson & Johnson will halt international sales of its Linx reflux device, sparking concern among surgeons over limited options for GERD patients.

Topics Bonds ETFs Economy

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

September 23, 2025

Via Benzinga

Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors ↗

September 23, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock ↗

September 23, 2025

Via Benzinga

The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now ↗

September 23, 2025

This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism ↗

September 23, 2025

Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears.

Via Benzinga

Topics Government Lawsuit

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? ↗

September 23, 2025

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty

Topics Government

September 22, 2025

As the perennial specter of a U.S. government shutdown once again casts a shadow over Washington, D.C., financial markets are bracing for potential turbulence. The failure of Congress to agree on...

The latest controversy poses a new reputational challenge for Kenvue, which was spun out of Johnson & Johnson in 2023.

Topics Bonds Economy

Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism ↗

September 22, 2025

Via Talk Markets

Topics Government

The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets

September 22, 2025

In an era marked by fluctuating interest rates, geopolitical uncertainties, and shifting economic landscapes, a select group of companies known as "Dividend Aristocrats" continues to shine as pillars...

In an era of fluctuating financial markets and evolving economic landscapes, the allure of dividend-paying stocks as a cornerstone for building long-term wealth remains as potent as ever. As investors...

Topics ETFs Economy Energy

The Unyielding Power of Dividends: A Blueprint for Enduring Wealth

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Topics Retirement Supply Chain

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

Topics Artificial Intelligence Economy Intellectual Property

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism ↗

Topics Artificial Intelligence Intellectual Property

September 22, 2025

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.